Kura Oncology (KURA) Competitors $6.46 +0.10 (+1.49%) Closing price 03:58 PM EasternExtended Trading$6.47 +0.01 (+0.23%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KURA vs. INDV, RXRX, DNLI, BEAM, KNSA, BLTE, CNTA, VCEL, IRON, and HRMYShould you be buying Kura Oncology stock or one of its competitors? The main competitors of Kura Oncology include Indivior (INDV), Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Kiniksa Pharmaceuticals International (KNSA), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), Vericel (VCEL), Disc Medicine (IRON), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Kura Oncology vs. Its Competitors Indivior Recursion Pharmaceuticals Denali Therapeutics Beam Therapeutics Kiniksa Pharmaceuticals International Belite Bio Centessa Pharmaceuticals Vericel Disc Medicine Harmony Biosciences Kura Oncology (NASDAQ:KURA) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings. Do analysts prefer KURA or INDV? Kura Oncology currently has a consensus target price of $24.50, suggesting a potential upside of 279.55%. Indivior has a consensus target price of $17.00, suggesting a potential upside of 8.93%. Given Kura Oncology's higher possible upside, analysts clearly believe Kura Oncology is more favorable than Indivior.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kura Oncology 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.86Indivior 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has more risk and volatility, KURA or INDV? Kura Oncology has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Indivior has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Does the media refer more to KURA or INDV? In the previous week, Kura Oncology had 2 more articles in the media than Indivior. MarketBeat recorded 2 mentions for Kura Oncology and 0 mentions for Indivior. Kura Oncology's average media sentiment score of 1.34 beat Indivior's score of 0.00 indicating that Kura Oncology is being referred to more favorably in the media. Company Overall Sentiment Kura Oncology Positive Indivior Neutral Do insiders & institutionals have more ownership in KURA or INDV? 60.3% of Indivior shares are owned by institutional investors. 6.4% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is KURA or INDV more profitable? Kura Oncology has a net margin of 0.00% compared to Indivior's net margin of -4.02%. Kura Oncology's return on equity of -43.62% beat Indivior's return on equity.Company Net Margins Return on Equity Return on Assets Kura OncologyN/A -43.62% -29.13% Indivior -4.02%-97.29%15.74% Which has stronger valuation and earnings, KURA or INDV? Indivior has higher revenue and earnings than Kura Oncology. Indivior is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKura Oncology$53.88M10.37-$173.98M-$2.10-3.07Indivior$1.19BN/A$2M-$0.31-50.34 SummaryKura Oncology beats Indivior on 8 of the 15 factors compared between the two stocks. Get Kura Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KURA vs. The Competition Export to ExcelMetricKura OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$558.81M$2.91B$5.48B$9.44BDividend YieldN/A2.48%4.00%4.04%P/E Ratio-3.0719.7628.0319.78Price / Sales10.37231.04422.7489.49Price / CashN/A40.8024.9928.17Price / Book1.217.608.125.68Net Income-$173.98M-$55.16M$3.24B$257.60M7 Day Performance1.65%1.81%1.07%1.84%1 Month Performance10.34%13.81%8.45%13.26%1 Year Performance-69.19%4.10%34.03%19.14% Kura Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KURAKura Oncology4.4975 of 5 stars$6.46+1.5%$24.50+279.6%-69.6%$558.81M$53.88M-3.07130Positive NewsINDVIndivior0.8646 of 5 stars$15.62+1.0%$17.00+8.8%+53.8%$2.15B$1.17B-50.391,051Upcoming EarningsRXRXRecursion Pharmaceuticals0.697 of 5 stars$5.28flat$7.00+32.6%-23.3%$2.15B$59.82M-2.98400Analyst RevisionGap UpDNLIDenali Therapeutics4.5887 of 5 stars$14.69+1.2%$33.71+129.5%-34.8%$2.13B$330.53M-5.50430BEAMBeam Therapeutics2.014 of 5 stars$21.17+0.0%$48.75+130.3%-20.0%$2.13B$63.52M-4.59510Analyst RevisionKNSAKiniksa Pharmaceuticals International3.4468 of 5 stars$28.80+2.5%$39.33+36.6%+36.7%$2.10B$423.24M-115.20220Upcoming EarningsBLTEBelite Bio2.1123 of 5 stars$63.58+0.6%$96.67+52.0%+21.0%$2.02BN/A-46.7510High Trading VolumeCNTACentessa Pharmaceuticals3.4956 of 5 stars$15.13+4.9%$27.89+84.3%+66.4%$2.02B$15M-8.36200Analyst ForecastHigh Trading VolumeVCELVericel3.7872 of 5 stars$39.82-0.3%$61.14+53.5%-29.5%$2.00B$238.54M1,327.78300News CoverageIRONDisc Medicine3.3623 of 5 stars$57.74+1.5%$96.70+67.5%+27.2%$2.00BN/A-14.7330News CoverageAnalyst ForecastInsider TradeGap UpHRMYHarmony Biosciences4.8302 of 5 stars$34.71+2.1%$51.33+47.9%+9.9%$1.99B$714.73M13.25200Positive NewsAnalyst Forecast Related Companies and Tools Related Companies INDV Alternatives RXRX Alternatives DNLI Alternatives BEAM Alternatives KNSA Alternatives BLTE Alternatives CNTA Alternatives VCEL Alternatives IRON Alternatives HRMY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KURA) was last updated on 7/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kura Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KURA Stock Alerts